Cargando…

Analytical and Clinical Performance of the Nanopia Krebs von den Lungen 6 Assay in Korean Patients With Interstitial Lung Diseases

BACKGROUND: Krebs von den Lungen 6 (KL-6) is a sensitive marker for diagnosing, monitoring, and predicting the prognoses of interstitial lung diseases (ILDs). This study aimed to evaluate the performance of the Nanopia KL-6 assay (Sekisui Medical, Tokyo, Japan) and to test the relationship between K...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cho, Eun-Jung, Park, Kyoung-Jin, Ko, Dae-Hyun, Koo, Hyun Jung, Lee, Sang Min, Song, Jin Woo, Lee, Woochang, Lee, Hae Kyung, Do, Kyung-Hyun, Chun, Sail, Min, Won-Ki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society for Laboratory Medicine 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340849/ https://www.ncbi.nlm.nih.gov/pubmed/30623616 http://dx.doi.org/10.3343/alm.2019.39.3.245

Ejemplares similares

Serum Krebs von den Lungen-6 level predicts disease progression in interstitial lung disease
por: Ko, Ui Won, et al.
Publicado: (2020)

Changes in blood Krebs von den Lungen-6 predict the mortality of patients with acute exacerbation of interstitial lung disease
por: Choi, Myeong Geun, et al.
Publicado: (2022)

Krebs von den Lungen-6 and surfactant protein-A in interstitial pneumonia with autoimmune features
por: Xue, Mingshan, et al.
Publicado: (2021)

1357. Initial and Peak Serum Levels of Krebs von den Lungen-6 for Prediction of Prognosis in Patients with COVID-19
por: Kim, Geonui, et al.
Publicado: (2023)

Krebs von den Lungen‐6 levels in untreated idiopathic pulmonary fibrosis
por: Jiang, Dingyuan, et al.
Publicado: (2022)

Krebs von den Lungen 6 decreased in the serum and muscle of GNE myopathy patients
por: Kurashige, Takashi, et al.
Publicado: (2020)

Role of Krebs von den Lungen-6 (KL-6) in Assessing Hypersensitivity Pneumonitis
por: Mostafa, Amira Ismail, et al.
Publicado: (2021)

The Prognostic Value of Krebs von den Lungen-6 and Surfactant Protein-A Levels in the Patients with Interstitial Lung Disease
por: Zheng, Peiyan, et al.
Publicado: (2021)

Distribution of Presepsin, Krebs von den Lungen 6, and Surfactant Protein A in Umbilical Cord Blood
por: Nam, Minjeong, et al.
Publicado: (2022)

Effects of molecular structural variants on serum Krebs von den Lungen-6 levels in sarcoidosis
por: Shigemura, Masahiko, et al.
Publicado: (2012)

Correlation of Krebs von den Lungen-6 and fibronectin with pulmonary fibrosis in coronavirus disease 2019
por: Peng, Ding-Hui, et al.
Publicado: (2021)

Exploring the Role of Krebs von den Lungen-6 in Severe to Critical COVID-19 Patients
por: D’Agnano, Vito, et al.
Publicado: (2022)

Serum Krebs von den Lungen-6: Promising biomarker to differentiate CPFE from IPF
por: Demirdöğen, Ezgi, et al.
Publicado: (2022)

Krebs von den Lungen-6 (KL-6) in cerebrospinal fluid from neurosarcoidosis patients
por: Bocci, Silvia, et al.
Publicado: (2023)

Blood Krebs von den Lungen-6 levels predict treatment response to antifibrotic therapy in patients with idiopathic pulmonary fibrosis
por: Choi, Myeong Geun, et al.
Publicado: (2022)

Clinical relevance of serum Krebs von den Lungen-6 levels in patients with coronavirus disease 2019
por: Chen, Hao, et al.
Publicado: (2021)

The value of serum Krebs von den lungen-6 as a diagnostic marker in connective tissue disease associated with interstitial lung disease
por: Ma, Hua, et al.
Publicado: (2020)

Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
por: Shirai, Yuichiro, et al.
Publicado: (2021)

Circulatory Serum Krebs von Den Lungen-6 and Surfactant Protein-D Concentrations Predict Interstitial Lung Disease Progression and Mortality
por: Rai, Meghna, et al.
Publicado: (2023)

Serum Krebs von den Lungen-6 levels are associated with mortality and severity in patients with coronavirus disease 2019
por: Yamaya, Takafumi, et al.
Publicado: (2021)

Baseline serum Krebs von den Lungen-6 as a biomarker for the disease progression in idiopathic pulmonary fibrosis
por: Chung, Chiwook, et al.
Publicado: (2022)

Krebs von den Lungen 6 (KL-6) levels in COVID-19 ICU patients are associated with mortality
por: Scarpati, Giuliana, et al.
Publicado: (2022)

Evaluation of the clinical performance of the HISCL‐5000 analyzer in the detection of Krebs von den Lungen‐6 antigen and its diagnostic value in interstitial lung disease
por: Wang, Jingxian, et al.
Publicado: (2019)

Krebs von den lungen-6 as a clinical marker for hypersensitivity pneumonitis: A meta-analysis and bioinformatics analysis
por: He, Jie, et al.
Publicado: (2022)

Novel Usefulness of Krebs von den Lungen 6 (KL-6) with Hemoglobin and Lactate Dehydrogenase for Assessing Bone Marrow Fibrosis
por: Nam, Minjeong, et al.
Publicado: (2022)

Comparative diagnostic efficacy of serum Krebs von den Lungen-6 and surfactant D for connective tissue disease-associated interstitial lung diseases: A meta-analysis
por: Zhong, Danli, et al.
Publicado: (2020)

Serum Krebs von den Lungen-6 for Predicting the Severity of COVID-19 Lung Injury: A Systematic Review and Meta-Analysis
por: Witarto, Andro Pramana, et al.
Publicado: (2021)

Krebs Von den Lungen-6 as a predictive indicator for the risk of secondary pulmonary fibrosis and its reversibility in COVID-19 patients
por: Xue, Mingshan, et al.
Publicado: (2021)

Impact of diabetes and Krebs von den Lungen‐6 on coronavirus disease 2019 severity: A single‐center study from Japan
por: Yakushiji, Yosuke, et al.
Publicado: (2022)

Krebs von den Lungen-6 (KL-6) Levels in Post-COVID Follow-Up: Differences According to the Severity of COVID-19
por: Carpio, Carlos, et al.
Publicado: (2023)

Krebs von den Lungen-6 (KL-6) as a clinical marker for severe COVID-19: A systematic review and meta-analyses
por: Naderi, Nadereh, et al.
Publicado: (2022)

Serum Krebs von den Lungen-6 for Predicting the Severity of COVID-19: A Systematic Review, Meta-Analysis, and Trial Sequence Analysis
por: Shrestha, Abhigan Babu, et al.
Publicado: (2023)

Prediction Value of KREBS Von Den Lungen-6 (KL-6) Biomarker in COVID-19 Patients: A Systematic Review and Meta-Analysis
por: Matuszewski, Michal, et al.
Publicado: (2022)

Serum levels of Krebs von den Lungen‐6 as a promising marker for predicting occurrence and deterioration of systemic sclerosis‐associated interstitial lung disease from a Chinese cohort
por: Cao, Xiao‐yu, et al.
Publicado: (2018)

Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II
por: d’Alessandro, Miriana, et al.
Publicado: (2022)

Krebs von den Lungen-6 glycoprotein circulating levels are not useful as prognostic marker in COVID-19 pneumonia: A large prospective cohort study
por: Castellví, Ivan, et al.
Publicado: (2022)

Histologic Chorioamnionitis, Amniotic Fluid Interleukin 6, Krebs von den Lungen 6, and Transforming Growth Factor β(1) for the Development of Neonatal Bronchopulmonary Dysplasia
por: Matsumura, Hisako, et al.
Publicado: (2017)

Krebs von den Lungen 6 (KL-6) as a marker for disease severity and persistent radiological abnormalities following COVID-19 infection at 12 weeks
por: Arnold, David T., et al.
Publicado: (2021)

Valeur pronostique du KL-6 initial (Krebs von den Lungen 6) au cours de la pneumopathie à SARS-CoV-2
por: Letellier, A., et al.
Publicado: (2022)

Serum concentrations of Krebs von den Lungen-6, surfactant protein D, and matrix metalloproteinase-2 as diagnostic biomarkers in patients with asbestosis and silicosis: a case–control study
por: Xue, Changjiang, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jp9s0aeunfr36ogssges9a60v0